Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer

Xiaodong Sun, Henry F. Frierson, Ceshi Chen, Changling Li, Qimei Ran, Kristen B. Otto, Brandi M. Cantarel, Robert L. Vessella, Allen C. Gao, John Petros, Yutaka Miura, Jonathan W. Simons, Jin Tang Dong

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Cancer often results from the accumulation of multiple genetic alterations. Although most malignancies are sporadic, only a small number of genes have been shown to undergo frequent mutations in sporadic cancers. The long arm of chromosome 16 is frequently deleted in human cancers, but the target gene for this deletion has not been identified1-4. Here we report that ATBF1, which encodes a transcription factor that negatively regulates AFP and MYB 5,6 but transactivates CDKN1A7, is a good candidate for the 16q22 tumor-suppressor gene. We narrowed the region of deletion at 16q22 to 861 kb containing ATBF1. ATBF1 mRNA was abundant in normal prostates but more scarce in approximately half of prostate cancers tested. In 24 of 66 (36%) cancers examined, we identified 22 unique somatic mutations, many of which impair ATBF1 function. Furthermore, ATBF1 inhibited cell proliferation. Hence, loss of ATBF1 is one mechanism that defines the absence of growth control in prostate cancer.

Original languageEnglish (US)
Pages (from-to)407-412
Number of pages6
JournalNature Genetics
Volume37
Issue number4
DOIs
StatePublished - Apr 1 2005

Fingerprint

Prostatic Neoplasms
Transcription Factors
Mutation
Neoplasms
Chromosomes, Human, Pair 16
Neoplasm Genes
Gene Deletion
Tumor Suppressor Genes
Prostate
Cell Proliferation
Messenger RNA
Growth
Genes

ASJC Scopus subject areas

  • Genetics

Cite this

Sun, X., Frierson, H. F., Chen, C., Li, C., Ran, Q., Otto, K. B., ... Dong, J. T. (2005). Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nature Genetics, 37(4), 407-412. https://doi.org/10.1038/ng1528

Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. / Sun, Xiaodong; Frierson, Henry F.; Chen, Ceshi; Li, Changling; Ran, Qimei; Otto, Kristen B.; Cantarel, Brandi M.; Vessella, Robert L.; Gao, Allen C.; Petros, John; Miura, Yutaka; Simons, Jonathan W.; Dong, Jin Tang.

In: Nature Genetics, Vol. 37, No. 4, 01.04.2005, p. 407-412.

Research output: Contribution to journalArticle

Sun, X, Frierson, HF, Chen, C, Li, C, Ran, Q, Otto, KB, Cantarel, BM, Vessella, RL, Gao, AC, Petros, J, Miura, Y, Simons, JW & Dong, JT 2005, 'Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer', Nature Genetics, vol. 37, no. 4, pp. 407-412. https://doi.org/10.1038/ng1528
Sun, Xiaodong ; Frierson, Henry F. ; Chen, Ceshi ; Li, Changling ; Ran, Qimei ; Otto, Kristen B. ; Cantarel, Brandi M. ; Vessella, Robert L. ; Gao, Allen C. ; Petros, John ; Miura, Yutaka ; Simons, Jonathan W. ; Dong, Jin Tang. / Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. In: Nature Genetics. 2005 ; Vol. 37, No. 4. pp. 407-412.
@article{c4f7aa4921784843b7bb361c8b360a7e,
title = "Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer",
abstract = "Cancer often results from the accumulation of multiple genetic alterations. Although most malignancies are sporadic, only a small number of genes have been shown to undergo frequent mutations in sporadic cancers. The long arm of chromosome 16 is frequently deleted in human cancers, but the target gene for this deletion has not been identified1-4. Here we report that ATBF1, which encodes a transcription factor that negatively regulates AFP and MYB 5,6 but transactivates CDKN1A7, is a good candidate for the 16q22 tumor-suppressor gene. We narrowed the region of deletion at 16q22 to 861 kb containing ATBF1. ATBF1 mRNA was abundant in normal prostates but more scarce in approximately half of prostate cancers tested. In 24 of 66 (36{\%}) cancers examined, we identified 22 unique somatic mutations, many of which impair ATBF1 function. Furthermore, ATBF1 inhibited cell proliferation. Hence, loss of ATBF1 is one mechanism that defines the absence of growth control in prostate cancer.",
author = "Xiaodong Sun and Frierson, {Henry F.} and Ceshi Chen and Changling Li and Qimei Ran and Otto, {Kristen B.} and Cantarel, {Brandi M.} and Vessella, {Robert L.} and Gao, {Allen C.} and John Petros and Yutaka Miura and Simons, {Jonathan W.} and Dong, {Jin Tang}",
year = "2005",
month = "4",
day = "1",
doi = "10.1038/ng1528",
language = "English (US)",
volume = "37",
pages = "407--412",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer

AU - Sun, Xiaodong

AU - Frierson, Henry F.

AU - Chen, Ceshi

AU - Li, Changling

AU - Ran, Qimei

AU - Otto, Kristen B.

AU - Cantarel, Brandi M.

AU - Vessella, Robert L.

AU - Gao, Allen C.

AU - Petros, John

AU - Miura, Yutaka

AU - Simons, Jonathan W.

AU - Dong, Jin Tang

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Cancer often results from the accumulation of multiple genetic alterations. Although most malignancies are sporadic, only a small number of genes have been shown to undergo frequent mutations in sporadic cancers. The long arm of chromosome 16 is frequently deleted in human cancers, but the target gene for this deletion has not been identified1-4. Here we report that ATBF1, which encodes a transcription factor that negatively regulates AFP and MYB 5,6 but transactivates CDKN1A7, is a good candidate for the 16q22 tumor-suppressor gene. We narrowed the region of deletion at 16q22 to 861 kb containing ATBF1. ATBF1 mRNA was abundant in normal prostates but more scarce in approximately half of prostate cancers tested. In 24 of 66 (36%) cancers examined, we identified 22 unique somatic mutations, many of which impair ATBF1 function. Furthermore, ATBF1 inhibited cell proliferation. Hence, loss of ATBF1 is one mechanism that defines the absence of growth control in prostate cancer.

AB - Cancer often results from the accumulation of multiple genetic alterations. Although most malignancies are sporadic, only a small number of genes have been shown to undergo frequent mutations in sporadic cancers. The long arm of chromosome 16 is frequently deleted in human cancers, but the target gene for this deletion has not been identified1-4. Here we report that ATBF1, which encodes a transcription factor that negatively regulates AFP and MYB 5,6 but transactivates CDKN1A7, is a good candidate for the 16q22 tumor-suppressor gene. We narrowed the region of deletion at 16q22 to 861 kb containing ATBF1. ATBF1 mRNA was abundant in normal prostates but more scarce in approximately half of prostate cancers tested. In 24 of 66 (36%) cancers examined, we identified 22 unique somatic mutations, many of which impair ATBF1 function. Furthermore, ATBF1 inhibited cell proliferation. Hence, loss of ATBF1 is one mechanism that defines the absence of growth control in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=20144389099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144389099&partnerID=8YFLogxK

U2 - 10.1038/ng1528

DO - 10.1038/ng1528

M3 - Article

VL - 37

SP - 407

EP - 412

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 4

ER -